For research use only. Not for therapeutic Use.
HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor with pIC50s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity[1].
HDAC-IN-4 inhibits HDAC1, HDAC2, HDAC3, HDAC8 and HDAC10 with pIC50s of 5.5, 4.6, 5.4, 5.4, 6.7 in FRET assay, respectively[1].
HDAC-IN-4 is more potent against HDAC6 than Tubastatin A, suggests that HDAC-IN-4 may be a better HDAC6 probe than Tubastatin A[1].
| Catalog Number | I045962 |
| CAS Number | 1252003-13-6 |
| Synonyms | N-hydroxy-4-[(2-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-9-yl)methyl]benzamide |
| Molecular Formula | C20H21N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H21N3O2/c1-22-11-10-17-16-4-2-3-5-18(16)23(19(17)13-22)12-14-6-8-15(9-7-14)20(24)21-25/h2-9,25H,10-13H2,1H3,(H,21,24) |
| InChIKey | JVELXRPQMVXDDP-UHFFFAOYSA-N |
| SMILES | CN1CCC2=C(C1)N(C3=CC=CC=C23)CC4=CC=C(C=C4)C(=O)NO |
| Reference | [1]. Géraldy M, et al. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem. 2019 May 9;62(9):4426-4443. |
